Articles related to MULTIPLE SCLEROSIS (MS)

In patients with early multiple sclerosis starting interferon beta-1a, serum neurofilament light chain levels predicted progression before MRI findings were considered, but did not provide independent long-term prognostic value after adjustment for baseline imaging.

The revised McDonald criteria recognize the cerebrospinal fluid κFLC index as an alternative to oligoclonal bands for demonstrating intrathecal immunoglobulin synthesis, expanding laboratory options while preserving the need for integrated MS diagnosis.

Among individuals with progressive multiple sclerosis, higher blood neurofilament light chain (NfL) levels were associated with lower daily ambulatory activity, while increases in NfL over time tended to track with subsequent declines in step counts measured by wearable devices.

Among newly diagnosed, treatment-naive patients with multiple sclerosis, gut microbiome profiles differed from healthy controls and were associated with MRI features linked to poorer prognosis, suggesting a potential future role for microbiome-based risk stratification.

An experimental cell therapy that couples a patient’s red blood cells with myelin protein fragments was well tolerated in a 10-patient Phase 1b study and was associated with increases in regulatory T-cells and reductions in neurofilament light chain, a biomarker linked to nerve injury.

A state Supreme Court reinstated a malpractice lawsuit involving delayed multiple sclerosis diagnosis after determining that unresolved questions remained regarding whether failure to communicate abnormal MRI findings may have deprived a patient of earlier treatment and a potentially better clinical position.